Keywords: imclone, 1st-qtr, revenues, rocket, systems, rapidly, moving

ImClone's 1st-qtr 2004 revenues rocket 459%

Article | 03 May 2004

ImClone Systems is rapidly moving away from troubled times brought on by the much-publicized insider trading scandal (Marketletters passim). The ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bristol-Myers Squibb

Go to company listing

Related Drugs

cetuximab

Erbitux

Go to drug listing